Have you ever heard of Secretariat? Secretariat was the

New Post Public Reply Private Reply Replies (2) Message Board
Respert24 Cassandra X #82408
613
Have you ever heard of Secretariat?

Secretariat was the greatest race horse to ever live, winning the last leg of the triple crown by 31 lengths. Unheard of. Unbelievable. Simply Amazing.

Everything we have been feeling and thinking about Leronlimab.

So now think about Leronlimab as Covid's Secretariat. A drug that's so much better than the standard of care that CD12 results should be a 31 length runaway win.

But it wasn't. Leronlimab finished outside of the money, a distant fourth.

Then some astute fellow wearing a derby hat and holding a rolled up copy of the daily racing form in his hands spits out what's left of his unfiltered cigarette and calmly asks to see a replay. Where it becomes clear that Leronlimab was held in the gate until well after the rest of the horses hit the half mile pole.

Well, that isn't fair.

How's a horse supposed to win if he doesn't get to start at the same time as the others? In fact he can't win. But wouldn't you know Leronlimab somehow made almost all of that half mile handicap up before it was over. His 1/4 and 1/2 mile fractions were way better than any other horse in the race. But he was only able to get up to fourth place before it was over and everyone who bet on Leronlimab lost.

It was a failure of a race.

The results of CD12 are not fishy. It's clear as day what happened. It was a rigged race. Leronlimab was randomly saddled with way more patients that were 3.5x more likely to die than the patients in the placebo arm. The placebo arm had a half mile lead in the race and even with that Leronlimab was able to show some significance and powerful stats that on any other day would likely result in a 31 length lead. Adding 140 more patients removes the half mile lead the placebo group had and will allow Leronlimab results to show exactly how many lengths ahead of the standard of care it really is.

Hopefully that helps you understand that nothing was rigged and nothing is fishy. Cytodyn got extremely unlucky with the randomization of patients and it was simply too much to overcome. The good news is that despite that terrible luck Leronlimab still showed some tremendous efficacy. We just need to rerun the first half the race without the gate malfunctioning.

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Centrus Energy Reports Q3 2024 Performance and Outlook

Updated Category News Views 497

Centrus Energy Corp. Announces Q3 2024 Results Centrus Energy Corp. (NYSE American: LEU) has released its third quarter results for 2024, showcasing both challenges and significant developments for the company. Despite a net loss, the company recorded $57.7 million in revenue, which marks a notable increase from the previous year. This report highlights key financial...

Continue Reading
Neuberger Berman Fund Unveils Rights Offering for Shareholders

Updated Category News Views 451

Neuberger Berman Real Estate Fund Announces a New Rights Offering Neuberger Berman Real Estate Securities Income Fund Inc. (NYSE American: NRO) has innovative news for its common stockholders. The Fund has revealed the issuance of transferable rights to allow current stockholders the opportunity to subscribe for additional shares of Common Stock at advantageous terms....

Continue Reading
ERES Announces January 2025 Cash Distribution Details

Updated Category News Views 131

ERES Announces January 2025 Cash Distribution European Residential Real Estate Investment Trust (TSX: ERE.UN, “ERES”) has made an important announcement regarding its monthly cash distribution for January 2025. This update clarifies earlier statements and provides shareholders with essential information regarding their investments. Details of the January 2025...

Continue Reading
Transforming Cemetery Sales: The Launch of Guidant

Updated Category News Views 371

Guidant: A Revolutionary Shift in Cemetery Property Sales Fortitude Research and Marketing has officially launched Guidant, an innovative technology company that is breaking new ground in the digital commerce landscape for cemeteries and funeral homes. This unique platform has enabled families to purchase cemetery property and related services directly online—something...

Continue Reading
Exciting Developments from Angel Yeast's Cup Finals Event

Updated Category News Views 139

Exciting Developments from Angel Yeast's Cup Finals Event Engaging the World Through Fermented Flour-Based Foods The Finals of the 8th Angel Yeast Cup Chinese Fermented Dim Sum Contest and the 12th Fermented Flour-Based Food Industry Development Conference recently concluded in a region acclaimed as the home of traditional Chinese staple foods. Angel Yeast Co., Ltd....

Continue Reading